

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Secukinumab for treating plaque psoriasis in children and young people

Batch 70

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

In response to consultation on the draft scope one comment stated “Since TA350 recommends Cosentyx for adults with psoriasis and the paediatric licence wording is expected to be the same as for adults, there would be an equality issue for children and adolescents if the secukinumab paediatric recommendations were restricted versus those for adults.”

This comment was noted, and the committee will consider whether any inequalities issues may arise (see below).

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

In appraising secukinumab within its extended marketing authorisation for moderate to severe plaque psoriasis in children and adolescents, the committee will have the opportunity to consider and address existing inequalities in access. The extent to which these equality issues can be addressed, and/or, different equality issues arise depends on the clinical and cost-effectiveness of secukinumab in the population covered by the extension to its marketing authorisation. The committee should be mindful of the extent to which their recommendations disadvantage a particular age group. The transitional period between potentially differing recommendations from older adolescence to adult care also needs consideration by the committee.

3. Has any change to the draft scope been agreed to highlight potential equality

issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

Approved by Associate Director: Henry Edwards

Date: 20/11/2020